Effect of the COVID-19 Pandemic Lockdown on the Management of Diabetic Retinopathy: A Cross-Sectional Study

被引:0
作者
Prajapati, Vaishali [1 ]
Shah, Krishna [1 ]
Shah, Dhruvi [1 ]
Wanjari, Mayur B. [2 ]
Singhal, Deepika [1 ]
机构
[1] GMERS Gujarat Med Educ & Res Soc Med Coll & Civil, Ophthalmol, Ahmadabad, India
[2] Datta Meghe Inst Med Sci Deemed Univ, Res, Jawaharlal Nehru Med Coll, Wardha, India
关键词
non-proliferative diabetic retinopathy (npdr); covid-19; fallout; etdrs classification; npdr; csme; diabetic retinopathy; PANRETINAL PHOTOCOAGULATION; INTRAVITREAL AFLIBERCEPT;
D O I
10.7759/cureus.27623
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Worldwide, diabetic retinopathy (DR) is one of the leading causes of vision loss. Early treatment and screening for DR have a major role in reducing the rate of the disease and the coronavirus disease 2019 (COVID-19) pandemic-related restrictions have altered real-world practice patterns in managing DR.Aims and objectives To evaluate the impact of the COVID-19 pandemic on the management of DR amongst patients presenting to a tertiary eye care center in Gujarat, India.Methods This is a cross-sectional study comparison of ophthalmic findings of 72 patients who presented to a tertiary care hospital with the manifestation of DR before and after the COVID-19 outbreak and subsequent lockdown. All the patients underwent detailed ophthalmic examinations, including optical coherence tomography (OCT) and fundus fluorescein angiography (FFA). Results The mean age of participants was 54.5 years, with the mean duration of diabetes being five years since first detected. Diabetes was present in 26 patients out of 72. The number of follow-up visits to an ophthalmologist before COVID-19 was at least every one to three months, which significantly decreased after the lockdown of COVID-19. We found a significant progression of DR and clinically significant macular edema (CSME) in patients with diabetes. Before COVID-19, there were two mild non-proliferative diabetic retinopathy (NPDR), seven moderate NPDR, 15 severe NPDR, and 15 very severe NPDR, which were increased post lockdown to three, nine, 27, and 21, respectively. The proliferative diabetic retinopathy (PDR) vitreous hemorrhage (VH) and tractional retinal detachment (TRD) were also increased to 12 after lockdown as compared to only six before the COVID-19 lockdown. The causes for progression are inability to attend regular check-ups, inability to take proper treatment of diabetes and DR, poor control of diabetes, episode of COVID-19, history of high dose of steroid use, poor kidney function, and not knowing that there is a progression of the disease. A common reason for not visiting an ophthalmologist was fear of the unknown due to COVID-19.Conclusions COVID-19 has severely impacted the routine follow-up of DR and, in the subsequent years, there might be an increased incidence of severe outcomes due to DR. The second wave of COVID-19 and its lockdown have had very significant effects on the visual outcome of untreated DR patients.
引用
收藏
页数:6
相关论文
共 16 条
  • [1] Mechanisms of Disease Diabetic Retinopathy
    Antonetti, David A.
    Klein, Ronald
    Gardner, Thomas W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (13) : 1227 - 1239
  • [2] Effect of COVID-19-Associated Lockdown on Patients With Diabetic Retinopathy
    Chatziralli, Irini
    Dimitriou, Eleni
    Kazantzis, Dimitrios
    Machairoudia, Genovefa
    Theodossiadis, Georgios
    Theodossiadis, Panagiotis
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (05)
  • [3] Transforming ophthalmic education into virtual learning during COVID-19 pandemic: a global perspective
    Chatziralli, Irini
    Ventura, Camila V.
    Touhami, Sara
    Reynolds, Rhianon
    Nassisi, Marco
    Weinberg, Tamir
    Pakzad-Vaezi, Kaivon
    Anaya, Denis
    Mustapha, Mushawiahti
    Plant, Adam
    Yuan, Miner
    Loewenstein, Anat
    [J]. EYE, 2021, 35 (05) : 1459 - 1466
  • [4] Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis
    Fallico, Matteo
    Maugeri, Andrea
    Lotery, Andrew
    Longo, Antonio
    Bonfiglio, Vincenza
    Russo, Andrea
    Avitabile, Teresio
    Pulvirenti, Alfredo
    Furino, Claudio
    Cennamo, Gilda
    Barchitta, Martina
    Agodi, Antonella
    Reibaldi, Michele
    [J]. ACTA OPHTHALMOLOGICA, 2021, 99 (06) : E795 - E805
  • [5] Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)
    Figueira, Joao
    Fletcher, Emily
    Massin, Pascale
    Silva, Rufino
    Bandello, Francesco
    Midena, Edoardo
    Varano, Monica
    Sivaprasad, Sobha
    Eleftheriadis, Haralabos
    Menon, Geeta
    Amaro, Miguel
    Scheer, Sarah Ayello
    Creuzot-Garcher, Catherine
    Nascimento, Joao
    Alves, Dalila
    Nunes, Sandrina
    Lobo, Conceicao
    Cunha-Vaz, Jose
    [J]. OPHTHALMOLOGY, 2018, 125 (05) : 691 - 700
  • [6] MECHANISMS OF DIABETIC COMPLICATIONS
    Forbes, Josephine M.
    Cooper, Mark E.
    [J]. PHYSIOLOGICAL REVIEWS, 2013, 93 (01) : 137 - 188
  • [7] Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy A Randomized Clinical Trial
    Gross, Jeffrey G.
    Glassman, Adam R.
    Liu, Danni
    Sun, Jennifer K.
    Antoszyk, Andrew N.
    Baker, Carl W.
    Bressler, Neil M.
    Elman, Michael J.
    Ferris, Frederick L.
    Gardner, Thomas W.
    Jampol, Lee M.
    Martin, Daniel F.
    Melia, Michele
    Stockdale, Cynthia R.
    Beck, Roy W.
    [J]. JAMA OPHTHALMOLOGY, 2018, 136 (10) : 1138 - 1148
  • [8] Intravitreal Aflibercept for Diabetic Macular Edema 148-Week Results from the VISTA and VIVID Studies
    Heier, Jeffrey S.
    Korobelnik, Jean-Franois
    Brown, David M.
    Schmidt-Erfurth, Ursula
    Do, Diana V.
    Midena, Edoardo
    Boyer, David S.
    Terasaki, Hiroko
    Kaiser, Peter K.
    Marcus, Dennis M.
    Nguyen, Quan D.
    Jaffe, Glenn J.
    Slakter, Jason S.
    Simader, Christian
    Soo, Yuhwen
    Schmelter, Thomas
    Vitti, Robert
    Berliner, Alyson J.
    Zeitz, Oliver
    Metzig, Carola
    Holz, Frank G.
    [J]. OPHTHALMOLOGY, 2016, 123 (11) : 2376 - 2385
  • [9] Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
    Korobelnik, Jean-Francois
    Loewenstein, Anat
    Eldem, Bora
    Joussen, Antonia M.
    Koh, Adrian
    Lambrou, George N.
    Lanzetta, Paolo
    Li, Xiaoxin
    Lovestam-Adrian, Monica
    Navarro, Rafael
    Okada, Annabelle A.
    Pearce, Ian
    Rodriguez, Francisco J.
    Wong, David T.
    Wu, Lihteh
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (06) : 1149 - 1156
  • [10] The RESTORE Study Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema
    Mitchell, Paul
    Bandello, Francesco
    Schmidt-Erfurth, Ursula
    Lang, Gabriele E.
    Massin, Pascale
    Schlingemann, Reinier O.
    Sutter, Florian
    Simader, Christian
    Burian, Gabriela
    Gerstner, Ortrud
    Weichselberger, Andreas
    [J]. OPHTHALMOLOGY, 2011, 118 (04) : 615 - 625